Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00811798
Other study ID # 111712
Secondary ID
Status Completed
Phase Phase 3
First received December 18, 2008
Last updated September 8, 2011
Start date May 2009
Est. completion date September 2010

Study information

Verified date September 2011
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority Hong Kong: Department of Health
Study type Interventional

Clinical Trial Summary

This study will collect safety data of GlaxoSmithKline Biologicals' human papillomavirus (HPV) vaccine in healthy females of Chinese origin who are unable to receive all three doses of commercially available HPV vaccine before they are 25 years, and were placebo recipients in the primary study (NCT00306241).


Recruitment information / eligibility

Status Completed
Enrollment 92
Est. completion date September 2010
Est. primary completion date September 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 25 Years and older
Eligibility Inclusion Criteria:

- Subjects enrolled in the primary study (NCT00306241) who received the placebo (aluminium hydroxide [Al(OH)3]).

- A female who is unable to receive all three doses of commercially available Cervarix before her 25th birthday.

- Written informed consent obtained from the subject (prior to enrolment).

- Healthy subjects as established by medical history and clinical examination before entering into the study.

- Subjects must have a negative urine pregnancy test.

- Subjects must be of non-childbearing potential or, if the subject is of childbearing potential, she must be abstinent (and if so, this must be documented in the source documents at each vaccination visit) or must be using adequate contraception for 30 days prior to vaccination and continue for two months after completion of the vaccination series.

Exclusion Criteria:

- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.

- Concurrently participating in another clinical study at any time during the study period, in which the subject has been or will be exposed to an investigational or non-investigational product (pharmaceutical product or device).

- Pregnant or breastfeeding.

- Planning to become pregnant or likely to become pregnant (as determined by the investigator) or planning to discontinue contraceptive prevention during the study period and up to two months after the last vaccine dose.

- History of allergic disease, suspected allergy or reactions likely to be exacerbated by any component of the study vaccine.

- Hypersensitivity to latex (found in syringe-tip cap and plunger).

- Known acute or chronic, clinically significant neurologic, haematological, hepatic or renal functional abnormality, as determined by previous physical examination or laboratory tests.

- Cancer or autoimmune disease under treatment.

- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.

- Previous administration of an adjuvant that used in the HPV-16/18 vaccine.

- Previous vaccination against HPV or planned administration of another HPV vaccine during the study.

- Acute disease at the time of enrolment.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Biological:
Cervarix
Subjects will receive three doses of the HPV vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.

Locations

Country Name City State
Hong Kong GSK Investigational Site Hong Kong

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Subjects Reporting Any Serious Adverse Event (SAE) and SAE(s) With a Causal Relationship to Vaccination as Assessed by the Investigator. SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects. During the entire study period (Day 0 up to the telephone contact at Month 12). No
See also
  Status Clinical Trial Phase
Completed NCT00359619 - Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine Phase 2
Completed NCT00250276 - Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation. Phase 3
Completed NCT01031069 - Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females Phase 4
Recruiting NCT05266898 - Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV Phase 4
Completed NCT03763565 - Effectiveness of HPV Vaccine in Thai Adult Women
Completed NCT00877877 - Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects. Phase 3
Recruiting NCT05884697 - Let's K-Talk - HPV Study for Ethnic Koreans N/A
Completed NCT00637195 - Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299) Phase 3
Completed NCT00798265 - A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults Phase 1
Completed NCT00423046 - Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age Phase 3
Completed NCT00294047 - Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older Phase 3
Recruiting NCT04469569 - Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors N/A
Not yet recruiting NCT04671823 - Changes in the Prevalence of Oncogenic HPV Types
Active, not recruiting NCT05148559 - Impact of Adolescent Vaccine Reminder Notices Sent Via Preferred Method of Communication on HPV Vaccination N/A
Recruiting NCT03350698 - Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination Phase 4
Completed NCT02370459 - AFIX to Improve HPV Vaccination N/A
Completed NCT00456807 - Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years Phase 3
Completed NCT03501992 - Multilevel Interventions to Enhance Provider Recommendations for HPV Vaccination N/A